Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients

Antimicrob Agents Chemother. 2015 Nov 23;60(2):1134-6. doi: 10.1128/AAC.02614-15. Print 2016 Feb.

Abstract

Few oral antibiotics exist for the empirical treatment of extended-spectrum β-lactamase (ESBL) urinary tract infections (UTI). In this study, we sought to determine the activity of fosfomycin against ESBL-producing uropathogens from patients at 3 Veterans Affairs (VA) facilities between 2010 and 2013. Among the ESBL uropathogens, 19.9% were fosfomycin resistant. Klebsiella species were more likely than Escherichia coli to be resistant (46% versus 4%; P < 0.001). Fosfomycin remains active against a majority of the ESBL uropathogens, although resistance among Klebsiella spp. was higher than that in previous reports.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Escherichia coli / drug effects
  • Escherichia coli / pathogenicity
  • Fosfomycin / pharmacology*
  • Fosfomycin / therapeutic use
  • Hospitals, Veterans
  • Humans
  • Klebsiella / drug effects
  • Klebsiella / pathogenicity
  • Male
  • Massachusetts
  • Microbial Sensitivity Tests
  • Urinary Tract Infections / drug therapy
  • Urinary Tract Infections / microbiology*
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Fosfomycin
  • beta-Lactamases